Pharmacy Bulletin 09-13-21

Pharmacy Bulletin 09-13-21

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

VativoRx Bottle update

Skytrofa® (lonapegsomatropin-tcgd) – New orphan drug approval

Ascendis Pharma announced the FDA approval of Skytrofa (lonapegsomatropin-tcgd), for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH). August 25, 2021

Briviact® (brivaracetam) – Expanded indication

UCB announced the FDA approval of Briviact (brivaracetam), for the treatment of partial-onset seizures in patients 1 month of age and older. August 30, 2021

Tecentriq® (atezolizumab) – Indication withdrawal

Roche announced the voluntary withdrawal of the Tecentriq (atezolizumab) indication for use in combination with paclitaxel protein-bound, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering ≥ 1% of the tumor area), as determined by an FDA-approved test. August 27, 2021

Tibsovo® (ivosidenib) – New indication

Servier Pharmaceuticals announced the FDA approval of Tibsovo (ivosidenib), for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Invega Hafyera Approved

Janssen’s Invega Hafyera™ (paliperidone palmitate) extended-release injectable suspension received approval from the U.S. Food and Drug Administration (FDA) on. It is a new longer-acting version of the atypical antipsychotic that is administered by intramuscular (IM) injections twice each year by a healthcare provider to treat adults who have schizophrenia. August 30, 2021

Trudhesa – FDA Approves

A new brand of dihydroergotamine (DHE) mesylate was FDA approved on. Impel NeuroPharma’s Trudhesa™ nasal spray is indicated to treat adults who have acute migraine headaches whether or not they are accompanied by auras. Sept 2, 2021

Brukinsa – Second Indication Awarded

Brukinsa® (zanubrutinib – BeiGene) capsules was FDA approved on Aug. 31, 2021, to treat adults who have Waldenström’s macroglobulinemia (WM). A rare type of non-Hodgkin lymphoma, WM is most common among older adults.

Keytruda Indication Revised

Accelerated Approval is given by the FDA for drugs that show promise for treating serious or life-threatening diseases in clinical studies, even though the studies have not been completed.

Teligent Pharma Recall

Teligent Pharma recalled one lot of lidocaine topical solution, 4% in 50mL bottles. Testing of samples from the recalled lot found it to be much stronger than indicated on the label. Aug. 27, 2021